Travere Therapeutics
Travere Therapeutics' revenue rose 110.5% to $491 million in fiscal 2025. Its operating margin was −12.8%, up from −138.9% a year earlier. The diluted share count rose 13.1%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What Travere Therapeutics does
Travere Therapeutics is a drug company based in San Diego that develops and sells medicines for rare kidney and metabolic diseases. Its main product is FILSPARI (sparsentan), which the U.S. Food and Drug Administration fully approved in September 2024 to slow the decline of kidney function in adults with primary IgA nephropathy, a rare, progressive kidney disease, who are at risk of getting worse. It had first won accelerated approval in February 2023. It also sells Thiola and Thiola EC, which treat cystinuria, a rare genetic disorder that causes recurring kidney stones.
It earns money by selling its approved medicines. As of the annual report, it was also seeking approval of FILSPARI for focal segmental glomerulosclerosis (FSGS), another rare kidney disease. It had asked the FDA for traditional approval, and the FDA's target date for a decision was extended to April 13, 2026.
It is also running a pivotal Phase 3 trial of pegtibatinase, an investigational enzyme replacement therapy for homocystinuria (HCU), a genetic disorder. It paused enrollment in September 2024 to improve the manufacturing process, and restarted it in the first quarter of 2026.
Its biggest risks, as it describes them
- Its future depends heavily on selling FILSPARI well and winning acceptance from doctors, patients and payers.
- Its late-stage programs may not win approval, including the FSGS application and pegtibatinase.
- It faces generic and other competition, and its medicines must prove advantages over other therapies.
- It depends on third parties to make and distribute its products.
- Healthcare reform, price controls and changes in insurance reimbursement could cut pricing and demand.
Income statement
Travere Therapeutics lost money in fiscal 2025: a net loss of $26 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 428 | 347 | 307 | — | 238 |
| Debt incl. finance leases | 227 | 376 | 377 | 379 | 312 |
| Net debt (negative means net cash) | −201 | 28 | 70 | — | 73 |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | 0.8x | 8.8x | 1.9x | 6.4x | 2.7x |
| Interest coverage | −10.1x | −29.1x | −34.4x | −29.0x | −5.8x |
| Current ratio | 4.7x | 3.4x | 3.5x | 2.1x | 2.7x |
| Quick ratio | 4.6x | 3.4x | 3.4x | 1.9x | 2.5x |
Cash flow
Projections
Project Travere Therapeutics' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
Over the 12 months between November 14, 2025 and November 13, 2026, no insider bought Travere Therapeutics shares on the open market, and 11 insiders sold $95.9 million, $94.5 million of it under trading plans set up in advance.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Sep 17, 2026 | Eric M DubeChief Executive Officer, Director | Sold plan | 108,493 | $64.61 | $7.0 million | Form 4 |
| Sep 17, 2026 | Peter HeermaEVP, Chief Commercial Officer | Sold plan | 8,282 | $65.07 | $538,910 | Form 4 |
| Sep 16, 2026 | Eric M DubeChief Executive Officer, Director | Sold plan | 195,841 | $63.45 | $12.4 million | Form 4 |
| Sep 16, 2026 | Peter HeermaEVP, Chief Commercial Officer | Sold plan | 172,717 | $63.43 | $11.0 million | Form 4 |
| Sep 16, 2026 | William E. RoteChief Research Officer | Sold plan | 112,850 | $63.33 | $7.1 million | Form 4 |
| Sep 15, 2026 | Peter HeermaEVP, Chief Commercial Officer | Sold plan | 102,190 | $62.26 | $6.4 million | Form 4 |
| Sep 15, 2026 | William E. RoteChief Research Officer | Sold plan | 96,198 | $62.25 | $6.0 million | Form 4 |
| Sep 15, 2026 | Eric M DubeChief Executive Officer, Director | Sold plan | 95,666 | $62.25 | $6.0 million | Form 4 |
| Sep 15, 2026 | Christopher R. ClineChief Financial Officer | Sold plan | 50,508 | $62.34 | $3.1 million | Form 4 |
| Sep 15, 2026 | Jula InrigEVP, Head of R&D & CMO | Sold plan | 44,674 | $62.34 | $2.8 million | Form 4 |
| Sep 15, 2026 | Elizabeth E ReedChief Legal Officer and GC | Sold plan | 37,500 | $62.34 | $2.3 million | Form 4 |
| Sep 15, 2026 | Sandra CalvinSVP, Chief Accounting Officer | Sold plan | 5,375 | $62.33 | $335,026 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | 4 of 9 | 3 of 9 | 7 of 9 |
| Rule of 40 | −160.6% | — | — |
| Altman Z'' | −3.95 | −9.10 | −5.38 |
| Accruals ratio | 23.1% | −12.2% | −10.6% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Pass |
| Return on assets rose | Pass | Fail | Pass |
| Cash from operations exceeds net income | Fail | Pass | Pass |
| Debt fell relative to assets | Pass | Fail | Pass |
| Current ratio rose | Pass | Fail | Pass |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | Fail | Pass | Pass |
| Revenue rose relative to assets | Pass | Pass | Pass |
| F-score | 4 of 9 | 3 of 9 | 7 of 9 |
Compare
Put Travere Therapeutics side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Travere Therapeutics | FY25 | 110.5% | −12.8% | — | — | — | 7 | |
| Mirum Pharmaceuticals | FY25 | 54.7% | −4.2% | 10.5% | −7.1% | −34.9x | 5 | Compare |
| Innoviva | FY25 | 14.7% | 39.8% | 47.6% | 17.9% | — | 6 | Compare |
| Ardelyx | FY25 | 22.1% | −10.1% | −10.8% | −36.1% | — | 2 | Compare |
| OPKO Health | FY25 | −14.9% | −19.4% | −31.4% | −7.0% | — | 4 | Compare |
10 years of figures
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | 134 | 155 | 164 | 175 | 198 | 132 | 110 | 145 | 233 | 491 |
| Revenue growth | 33.7% | 16.0% | 6.0% | 6.8% | 13.1% | −33.5% | −17.0% | 32.7% | 60.5% | 110.5% |
| Gross profit | 129 | 151 | 159 | 170 | 192 | 128 | 105 | 134 | 225 | 480 |
| Research and development | 71 | 78 | 124 | 141 | 132 | 201 | 8 | 245 | 218 | 206 |
| Operating income | −58 | −54 | −80 | −137 | −176 | −199 | −320 | −388 | −324 | −63 |
| Net income | −48 | −60 | −103 | −146 | −169 | −180 | −278 | −111 | −322 | −26 |
| Diluted EPS (US$) | −1.29 | −1.54 | −2.54 | −3.46 | −3.56 | −3.01 | −4.37 | −1.50 | −4.08 | −0.29 |
| Diluted shares (millions) | 38 | 39 | 40 | 42 | 48 | 60 | 64 | 74 | 79 | 89 |
| Cash flow | ||||||||||
| Cash from operations | −3 | 7 | −25 | −58 | −43 | −15 | −186 | −280 | −238 | 38 |
| Capital expenditure | 1 | 1 | 1 | 0 | 7 | 5 | 0 | 1 | — | — |
| Free cash flow | −5 | 7 | −26 | −58 | −50 | −20 | −186 | −281 | — | — |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 1 | 0 | 0 | 0 | 95 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 29 | 27 | 20 | 21 | 24 | 30 | 38 | 44 | 37 | 45 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 41 | 223 | 311 | 272 | 357 | 428 | 347 | 307 | — | 238 |
| Debt incl. finance leases | 44 | 45 | 218 | 205 | 215 | 227 | 376 | 377 | 379 | 312 |
| Total assets | 525 | 520 | 709 | 605 | 607 | 777 | 673 | 789 | 594 | 605 |
| Total liabilities | 218 | 227 | 391 | 384 | 396 | 474 | 630 | 588 | 535 | 490 |
| Shareholders' equity | 308 | 293 | 318 | 221 | 211 | 302 | 43 | 201 | 59 | 115 |
| Margins and ratios | ||||||||||
| Gross margin | 96.6% | 97.7% | 96.6% | 97.0% | 96.9% | 97.1% | 96.0% | 92.1% | 96.7% | 97.9% |
| Operating margin | −43.6% | −34.7% | −48.7% | −78.3% | −88.8% | −151.3% | −292.2% | −267.2% | −138.9% | −12.8% |
| Net margin | −35.9% | −38.5% | −62.5% | −83.5% | −85.4% | −136.6% | −254.4% | −76.7% | −137.9% | −5.2% |
| Free cash flow margin | −3.6% | 4.2% | −15.6% | −33.3% | −25.0% | −15.1% | −170.4% | −193.3% | — | — |
| Rule of 40 (growth + FCF margin) | 30.1% | 20.2% | −9.6% | −26.6% | −11.9% | −48.6% | −187.3% | −160.6% | — | — |
| Return on capital | −14.9% | −19.9% | −37.2% | −57.3% | −124.2% | −184.6% | −293.9% | −179.1% | — | — |
| Return on equity | −15.8% | −19.9% | −33.6% | −54.3% | −78.4% | −70.2% | −161.5% | −91.4% | −247.4% | −29.4% |
| Return on assets | −9.2% | −11.4% | −16.7% | −22.3% | −27.9% | −26.0% | −38.4% | −15.2% | −46.5% | −4.3% |
| Net debt to EBITDA | — | — | — | — | — | — | — | — | — | — |